Broadway Financial Corporation shares rise 1.71% intraday after positive Phase 3 data for obicetrapib.

Broadway Financial Corporation rose 1.71% intraday, with the company announcing late-breaking data from the BROADWAY and TANDEM trials presented at EAS 2025. The Phase 3 data showed that obicetrapib, as an adjunct to statins, reduced LDL-C by 50% and 35%, respectively. Additionally, Phase 2 data of obicetrapib in combination with moderate-dose statins showed LDL-C reductions of approximately 70%. The BROADWAY trial also observed a 21% reduction in major adverse cardiovascular events.